Leerink Partnrs Has Bearish Outlook for Geron Q2 Earnings

Geron Co. (NASDAQ:GERN) – Stock analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for Geron in a research report issued on Thursday, November 7th. Leerink Partnrs analyst F. Khurshid now expects that the biopharmaceutical company will post earnings of $0.01 per share for the quarter, down from their previous estimate of $0.02. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.34) per share. Leerink Partnrs also issued estimates for Geron’s Q4 2025 earnings at $0.06 EPS, FY2025 earnings at $0.10 EPS and FY2026 earnings at $0.33 EPS.

Several other analysts have also issued reports on the stock. HC Wainwright began coverage on shares of Geron in a research report on Tuesday, November 5th. They set a “buy” rating and a $8.00 price target for the company. StockNews.com upgraded Geron to a “sell” rating in a report on Monday, August 5th. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price target on shares of Geron in a research note on Thursday, August 8th. Scotiabank began coverage on Geron in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 target price on shares of Geron in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $7.05.

Geron Price Performance

Shares of Geron stock opened at $3.97 on Monday. The firm has a market capitalization of $2.40 billion, a PE ratio of -12.41 and a beta of 0.52. The company has a current ratio of 3.61, a quick ratio of 3.60 and a debt-to-equity ratio of 0.12. Geron has a 12 month low of $1.64 and a 12 month high of $5.34. The business’s 50-day moving average price is $4.29 and its 200-day moving average price is $4.32.

Geron (NASDAQ:GERN) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.05. Geron had a negative net margin of 682.48% and a negative return on equity of 67.10%. The company had revenue of $28.27 million during the quarter, compared to analyst estimates of $18.97 million. During the same period in the previous year, the business earned ($0.08) earnings per share. The firm’s quarterly revenue was up 17138.4% compared to the same quarter last year.

Institutional Investors Weigh In On Geron

Several institutional investors and hedge funds have recently modified their holdings of GERN. National Bank of Canada FI increased its position in shares of Geron by 1,200.0% during the second quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 6,000 shares during the period. Crewe Advisors LLC grew its holdings in shares of Geron by 870.0% during the 1st quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 8,700 shares during the period. Kingsview Wealth Management LLC purchased a new position in shares of Geron during the 1st quarter worth approximately $34,000. American Trust bought a new position in shares of Geron in the 1st quarter worth approximately $38,000. Finally, Rovin Capital UT ADV purchased a new position in shares of Geron in the 3rd quarter valued at approximately $62,000. 73.71% of the stock is owned by hedge funds and other institutional investors.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.